Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?
Gurewich
V
V
Vascular Research Laboratory, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Muller
J
J
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D013300:Streptokinase / Q000009:adverse effects; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator